# Freek W.A. Verheugt

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/freek-w-a-verheugt/

## Facts

| Field | Value |
| --- | --- |
| Citations | 52,703 |
| Field | Atrial Fibrillation Management and Outcomes |
| h-index | 82 |
| i10-index | 221 |
| Last Known Institution | Radboud University Nijmegen |
| OpenAlex ID | https://openalex.org/A5065978967 |
| ORCID iD | https://orcid.org/0000-0002-5831-6951 |
| Works | 460 |

## Researcher papers

- [Apixaban versus Warfarin in Patients with Atrial Fibrillation](https://scholariq.org/papers/apixaban-versus-warfarin-in-patients-with-atrial-fibrillation/)
- [2012 focused update of the ESC Guidelines for the management of atrial fibrillation](https://scholariq.org/papers/2012-focused-update-of-the-esc-guidelines-for-the-management-of-atrial/)
- [ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008](https://scholariq.org/papers/esc-guidelines-for-the-diagnosis-and-treatment-of-acute-and-chronic-heart-3/)
- [2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS](https://scholariq.org/papers/2017-esc-focused-update-on-dual-antiplatelet-therapy-in-coronary-artery-disease/)
- [ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM)](https://scholariq.org/papers/esc-guidelines-for-the-diagnosis-and-treatment-of-acute-and-chronic-heart/)
- [Rivaroxaban in Patients with a Recent Acute Coronary Syndrome](https://scholariq.org/papers/rivaroxaban-in-patients-with-a-recent-acute-coronary-syndrome/)
- [Apixaban with Antiplatelet Therapy after Acute Coronary Syndrome](https://scholariq.org/papers/apixaban-with-antiplatelet-therapy-after-acute-coronary-syndrome/)
- [Early thrombolysis in acute myocardial infarction: Limitation of infarct size and improved survival](https://scholariq.org/papers/early-thrombolysis-in-acute-myocardial-infarction-limitation-of-infarct-size-and/)
- [IMPROVED SURVIVAL AFTER EARLY THROMBOLYSIS IN ACUTE MYOCARDIAL INFARCTION](https://scholariq.org/papers/improved-survival-after-early-thrombolysis-in-acute-myocardial-infarction/)
- [Bleeding in acute coronary syndromes and percutaneous coronary interventions: position paper by the Working Group on Thrombosis of the European Society of Cardiology](https://scholariq.org/papers/bleeding-in-acute-coronary-syndromes-and-percutaneous-coronary-interventions/)
- [Parenteral anticoagulants in heart disease: Current status and perspectives (Section II)](https://scholariq.org/papers/parenteral-anticoagulants-in-heart-disease-current-status-and-perspectives/)
- [Vitamin K antagonists in heart disease: Current status and perspectives (Section III)](https://scholariq.org/papers/vitamin-k-antagonists-in-heart-disease-current-status-and-perspectives-section/)

## Researcher topics

- [Atrial Fibrillation Management and Outcomes](https://scholariq.org/topics/atrial-fibrillation-management-and-outcomes/)
- [Antiplatelet Therapy and Cardiovascular Diseases](https://scholariq.org/topics/antiplatelet-therapy-and-cardiovascular-diseases/)
- [Acute Myocardial Infarction Research](https://scholariq.org/topics/acute-myocardial-infarction-research/)
- [Venous Thromboembolism Diagnosis and Management](https://scholariq.org/topics/venous-thromboembolism-diagnosis-and-management-2/)
- [Coronary Interventions and Diagnostics](https://scholariq.org/topics/coronary-interventions-and-diagnostics/)

## Researcher university

- [Radboud University Nijmegen](https://scholariq.org/institutions/radboud-university-nijmegen/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.